BioXcel Therapeutics (FRA:BX20) Short-Term Debt: €90.66 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BX20 BioXcel Therapeutics Inc FRA:BX20
19 GF Score
Price €0.67
GF Value €0.45
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Short-Term Debt?

BioXcel Therapeutics FRA:BX20 -3.72% 19 Short-Term Debt is €90.66 Mil as of Jun. 2026. GuruFocus rates FRA:BX20 with a GF Score™ of 19/100 and a GF Value™ of €0.45 (Significantly Overvalued). The stock has 3 warning signs investors should review.

BioXcel Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2026 was €90.66 Mil.

BioXcel Therapeutics's quarterly Short-Term Debt declined from Dec. 2025 (€21.29 Mil) to Mar. 2026 (€19.40 Mil) but then increased from Mar. 2026 (€19.40 Mil) to Jun. 2026 (€90.66 Mil).

BioXcel Therapeutics's annual Short-Term Debt stayed the same from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then increased from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€21.29 Mil).

BioXcel Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

BioXcel Therapeutics Short-Term Debt Related Terms

BioXcel Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for BioXcel Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics Short-Term Debt Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 21.29

BioXcel Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.72 14.33 21.29 19.40 90.66
FRA:BX20
19GF Score
BioXcel Therapeutics Inc FRA:BX20
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €90.66 Mil mean?
BioXcel Therapeutics (FRA:BX20) has a Short-Term Debt of €90.66 Mil as of Jun. 2026.
Is BioXcel Therapeutics' Short-Term Debt too high?
BioXcel Therapeutics' current Short-Term Debt is €90.66 Mil. Overall, BioXcel Therapeutics has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Short-Term Debt compare to MRMD and RMTI?
BioXcel Therapeutics' Short-Term Debt of €90.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. BioXcel Therapeutics's current Short-Term Debt is €90.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (FRA:BX20) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.45, compared to a current price of €0.67 — trading 49.3% above its estimated fair value. The current Short-Term Debt is €90.66 Mil. BioXcel Therapeutics' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For BioXcel Therapeutics (FRA:BX20), the current Short-Term Debt is €90.66 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioXcel Therapeutics (FRA:BX20) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of €0.67 is trading 49.3% above its estimated GF Value™ of €0.45. GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:BX20:

  • Short-Term Debt: €90.66 Mil
  • GF Value™: €0.45 vs. price of €0.67 (49.3% above fair value)
  • GF Score™: 19/100 with 3 warning signs

No single metric tells the full story. See the FRA:BX20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BTAI:USA
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
19GF Score

Get the complete analysis for FRA:BX20

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.67
Price
€0.45
GF Value